Word: crixivan
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...particular drug company has been a significant player in Botswana: Merck. The U.S. firm created some of the first ARVs capable of treating HIV and AIDS (Crixivan and Stocrin), but has in the past been criticized for its methods of distributing them. In 2004, MSF singled out Merck for reneging on commitments to release the medicines at a cost of less than $1 per person per day. Merck was hurt by such accusations. (According to the firm's website, its founder, George W. Merck, once said: "We try never to forget that medicine is for the people...
...public relations woes, Bristol-Meyers-Squibb Pharmaceuticals announced last week that it would market its AIDS drugs, Zerit and Videx, to Africa at a combined price of $1 per day. This follows closely on the heels of Merck Pharmaceuticals' announcement that it would market its drug, the protease inhibitor Crixivan, to Africa at the reduced price of $600 per year. AIDS drugs typically cost between $10,000 and $15,000 per year. Needless to say, because of these exorbitantly high prices, these drugs are out of reach for those most in need--especially those in sub-Saharan Africa, quickly becoming...
...deadly stalemate seems to be breaking up. Last week, even as the big pharmaceutical companies went to court to keep generic copies of their drugs out of South Africa, one of the biggest of these, Merck, announced it would slash prices of two of its major AIDS drugs, Crixivan and Stocrin, an additional 40% to 55%. Other drug giants--including GlaxoSmithKline and Bristol-Myers Squibb--immediately signaled they would follow suit...
TORONTO: Could patients be developing an immunity to parts of the chemical cocktail that has proven so effective in fighting HIV? The announcement to this effect by Dr. Steven Deeks, a University of San Francisco AIDS researcher, that people might be developing an immunity to the protease inhibitors Crixivan and Norvir has left many questioning whether the highly-expensive treatment would remain worthwhile. A study of 136 HIV-positive people who started using the inhibitors in March of 1996 showed that within a year the virus had returned to detectable levels in about 53 percent...
...strong research efforts over the past decade are beginning to pay off. Crixivan, a Merck product, was one-third of the promising "drug cocktail" released last year to treat AIDS. Merck also released Fosamax, a treatment for osteoporosis, which affects one-third of all women over 60. This year, Merck has already introduced nine drug products, Gilmartin said...